In Japanese patients with osteoporosis, teriparatide increased lumbar spine BMD by at least 10% across baseline subgroups through 24 months.
In plain wordsIn Japanese patients with osteoporosis, teriparatide increased spine bone density from baseline across all measured subgroups.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- IncreaseLumbar spine BMD across baseline subgroups
- Study
n: not reported in source
- Analysis
- Exploratory
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- 20 μg/day · subcutaneous · 24 monthsAs given in this study (human).
Measurements
- Lumbar spine BMD increase
- ≥ 10%
- all subgroups through 24 months
Source sentences
Teriparatide increased lumbar spine BMD in all subgroups by 10 % or more through 24 months.
2 context sentences(design, population, supporting numbers)
In this previously reported multicenter study, teriparatide 20 μg/day was administered to elderly Japanese subjects (93 % female; median age 70 years) with osteoporosis and at high risk of fracture during a 12-month, randomized, double-blind, placebo-controlled period, which was followed by a 12 mon…
This was an exploratory analysis to determine whether the baseline status of serum bone turnover markers (BTMs) and vitamin D levels affect the efficacy of teriparatide at 20 μg/day.